A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)

This publication has 24 references indexed in Scilit:

• Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study
  European Heart Journal, 2006
• A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II)
  Journal of the American College of Cardiology, 2005
• Cardioprotective effect of MCC-135 is associated with inhibition of Ca2+ overload in ischemic/reperfused hearts
  European Journal of Pharmacology, 2004
• Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
  Circulation, 2003
• Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction
  Circulation, 2003
• Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
  New England Journal of Medicine, 2002
• Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
  New England Journal of Medicine, 2001
• Cardiac Na ⁺ -Ca ²⁺ Exchange
  Circulation Research, 2001
• Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction
  Journal of the American College of Cardiology, 1999
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
  The Lancet, 1998